<DOC>
	<DOCNO>NCT01712425</DOCNO>
	<brief_summary>The HIVconsv gene construct assemble 14 conserved region HIV-1 proteome one chimaeric protein . This gene insert 2 leading non-replicating vaccine vector : attenuate chimpanzee adenovirus serotype 63 ( ChAdV63 ) modify vaccinia virus Ankara ( MVA ) construct ChAdV63.HIVconsv MVA.HIVconsv HIV-1 candidate vaccine . The present study name ChAd-MVA.HIVconsv-BCN01 phase I , multicenter primary/booster therapeutic vaccination study evaluate safety immunogenicity ChAdV63.HIVcons MVA.HIVconsv HIV-1 vaccine , deliver intramuscularly accord 0-8 week 0-24 week schedule recently HIV-1 infected individual early viral suppression 6 month initiation Tenofovir/Emtricitabine plus Raltegravir .</brief_summary>
	<brief_title>Safety Immunogenicity ChAdV63.HIVconsv MVA.HIVconsv Candidate HIV-1 Vaccines Recently HIV-1 Infected Individuals</brief_title>
	<detailed_description>It Phase I , multicenter primary/booster therapeutic vaccination study evaluate safety immunogenicity ChAdV63.HIVcons MVA.HIVconsv HIV-1 vaccine , deliver intramuscularly accord 0-8 week 0-24 week schedule recently HIV-1 infected individual early viral suppression 6 month initiation Tenofovir/Emtricitabine plus Raltegravir . 24 patient meet eligibility criterion enrol , first 10 individual assign 0-24 week prime/boost regimen ( ARM A ) . The next 10 volunteer assign 0-8 week prime/boost regimen ( ARM B ) .Four additional volunteer include 'back-up ' assign 2 ARM A 2 ARM B cover possible 10 % patient drop-off follow-up . Purpose stag 2 study arm shorten overall study duration ( screen first volunteer 6 month last immunisation last volunteer ) . Lastly , 24 patient also meet eligibility criterion enrol control , also initiate promptly antiretroviral treatment Tenofovir/Emtricitabine plus Raltegravir receive investigational vaccine . Control patient consecutively assign 0-24w control arm ( ARM C 'long control ' ) 0-8w control arm ( ARM D 'short control ' ) 12 patient per arm reach . The purpose control arm study population compare viral reservoir decay kinetics absence vaccination .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female , age 1860 year 2 . Confirmed HIV1 seropositive document past 6 month ( acute antiretroviral syndrome , p24 antigenemia and/or ELISA seroconversion ) 3 . Willing able give write informed consent participation study 4 . Willing able adhere effective HAART regimen duration study 5 . Cluster differentiation 4 ( CD4 ) + T cell count &gt; 350 cells/ml screen precede clinic visit 6 . No new AIDSdefining diagnosis progression HIVrelated disease . 7 . Haematological biochemical laboratory parameter follow : Haemoglobin &gt; 10g/dl , Platelets &gt; 100.000/dl , alanine aminotransferase ( ALT ) ≤ 2.5 x ULN , Creatinine ≤ 1.3 x upper limit normal ( ULN ) 8 . Serology : negative hepatitis B surface antigen OR HbsAg positive Hepatitis B Virus ( HBV ) DNA &lt; 1000 copies/ml ; negative hepatitis C antibodies OR confirm clearance Hepatitis C Virus ( HCV ) infection ( spontaneous follow treatment ) ; negative syphilis serology document adequate treatment syphilis positive enzimeimmunoassay ( EIA ) Immonoglobulin G ( IgG ) Treponema pallidum hemagglutination assay ( TPHA ) 9 . Available follow duration study ( screen + 72 week ) willing comply protocol requirement 10 . Women childbearing age must pregnant , plan pregnancy breastfeeding . Sexually active woman must willing use approve method contraception screen 4 month second immunisation . Sexually active men heterosexual relationship must willing use approve method contraception partner screen 4 month second immunisation . 1 . Confirmed HIV2 seropositive 2 . Positive pregnancy test 3 . Presence Nucleos ( ) ide Reverse Transcriptase Inhibitors ( NRTI ) mutation screen genotype 4 . Participation another clinical trial within 12 week study entry 5 . History autoimmune disease HIVrelated autoimmune disease . 6 . History clinical manifestation physical psychiatric disorder could impair subject 's ability complete study 7 . History anaphylaxis severe adverse reaction vaccine 8 . Previous immunisation experimental immunogens 9 . Receipt blood product within 6 month study entry 10 . Treatment cancer lymphoproliferative disease within 1 year study entry 11 . Receipt vaccine Hepatitis B vaccine within 2 week study entry plan receipt within 2 week vaccination 12 . Any prior therapy , opinion investigator , would make individual unsuitable study influence result study 13 . Current recent use ( within last 3 month ) interferon systemic corticosteroid immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>recently HIV-1 infected individual</keyword>
</DOC>